演題概要

ポスター発表

第3日　5月21日（金）　　P2会場（Zoom）

3P-41　　PDF

自動化免疫沈降法とMALDI-TOF MSを用いた血漿アミロイドβバイオマーカーの性能

(¹島津・ ²長寿研)
^o金子直樹¹・ 中村昭範²・ 依田里都子¹・ 加藤隆司²・ 関谷禎規¹・ 伊藤健吾²・ 岩本慎一¹・ 柳澤勝彦²・ 田中耕一¹

Abnormal amyloid-β (Aβ) deposition in the brain has been defined as the earliest pathological change of Alzheimer disease (AD). Using immunoprecipitation (IP) combined with MALDI-TOF MS, we have previously reported that the composite biomarker, which is a combination of APP669-711/Aβ1-42 ratio and Aβ1-40/ Aβ1-42 ratio in human plasma, correlates with amyloid PET status. In this study, we constructed an automated IP system for high-throughput analysis and then evaluated the biomarker performance by measuring 41 Aβ+ and 55 Aβ- subjects classified using PET with PIB tracer. In a receiver operating characteristic (ROC) analysis, MALDI-TOF MS with the automated IP showed high area under the ROC curves and accuracy in the three biomarkers.